---
title: "Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292932773.md"
description: "H.C. Wainwright analyst Joseph Pantginis reaffirmed a Buy rating on Adlai Nortye with a $20 price target, citing the strategic advancement of its AN9025 dual-arm clinical strategy. The intermittent weekly dosing arm, supported by preclinical data showing sustained tumor control, aims to improve the therapeutic window and manage toxicity. This approach addresses class-wide safety constraints of pan-RAS inhibitors, reinforcing confidence in the company's pipeline and long-term value."
datetime: "2026-07-16T16:45:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292932773.md)
  - [en](https://longbridge.com/en/news/292932773.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292932773.md)
generator: "portal-rs"
---

# Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Adlai Nortye Ltd. Sponsored ADR, with a price target of $20.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Joseph Pantginis has given his Buy rating due to a combination of factors, notably the strategic advancement of AN9025 into an intermittent weekly dosing arm alongside the ongoing daily regimen. He views this dual-arm Phase 1 design as expanding the program’s opportunities, while the unchanged $20 price target reflects confidence that this broader clinical approach can enhance the asset’s long-term value.

Pantginis highlights that the weekly schedule is grounded in preclinical data showing sustained tumor control even during drug holidays, supporting a hypothesis of improved therapeutic window and manageable toxicity. He also underscores that Adlai Nortye is tackling the class-wide safety constraints of pan-RAS(ON) inhibitors through both innovative scheduling with AN9025 and targeted delivery via its RASiCA-based ADC AN4035, reinforcing his constructive outlook on the company’s pipeline and risk-reward profile.

### Related Stocks

- [ANL.US](https://longbridge.com/en/quote/ANL.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)

## Related News & Research

- [Major Insider Move Shakes Up Adlai Nortye’s Market Narrative](https://longbridge.com/en/news/297118427.md)
- [Seven Fleet Capital Management LP Acquires New Stake in Adlai Nortye Ltd. Sponsored ADR $ANL](https://longbridge.com/en/news/297167000.md)
- [Insider Selling: Adlai Nortye (NASDAQ:ANL) CFO Sells $80,754.75 in Stock](https://longbridge.com/en/news/297176514.md)
- [Mira Pharmaceuticals reports positive 7-day rat, dog tox studies for oral pain drug MIRA-55 ahead of IND push](https://longbridge.com/en/news/297649032.md)
- [HCW Biologics wins USPTO patent allowance for HCW9302 use in alopecia areata treatment](https://longbridge.com/en/news/297790650.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**